Skip to main content
Erschienen in:

06.04.2020 | Gynecologic Oncology

Fertility-sparing surgery for patients with malignant ovarian germ cell tumors: 10 years of clinical experience from a tertiary referral center

verfasst von: Mislav Mikuš, Nikolina Benco, Luka Matak, Pavao Planinić, Mario Ćorić, Helena Lovrić, Velena Radošević, Tomislav Puževski, Mirna Bajt, Goran Vujić

Erschienen in: Archives of Gynecology and Obstetrics | Ausgabe 5/2020

Einloggen, um Zugang zu erhalten

Abstract

Purpose

To describe a case series of patients with malignant ovarian germ cell tumors (MOGCT) treated exclusively with fertility-sparing surgery (FSS) with or without adjuvant chemotherapy.

Methods

We retrospectively reviewed the records of 27 patients with MOGCT treated in the Department of Obstetrics and Gynecology, University Hospital Center Zagreb, Croatia, between January 2009 and July 2019.

Results

The median age at diagnosis was 22 years, and the main symptom was abdominal distension (57.0%). The most prevalent histological subtype was immature teratoma (n = 13, 48.1%). Twenty-three patients (85.2%) had laparotomy and 4 (14.8%) had laparoscopy, without conversions. Lymphadenectomy was performed in 16 (59.3%) patients, with 184 removed lymph nodes, and omentectomy was performed in 19 (70.4%) patients. The rate of chemotherapy administration was 81.5%. The follow-up length ranged between 6.30 and 115.1 months (median: 49.60 months). No patient experienced tumor recurrence. The rate of complete gross resection was 100%. At the time of analysis, all patients were alive and disease free. Fifty percent of patients who actively tried to conceive after FSS became pregnant, with 12 deliveries.

Conclusion

This study suggests that FSS is a safe treatment option for MOGCT, regardless of tumor stage and histological type.
Literatur
1.
Zurück zum Zitat Tamauchi S, Kajiyama H, Yoshihara M, Ikeda Y, Yoshikawa N, Nishino K, Utsumi F, Niimi K, Suzuki S, Kikkawa F (2018) Reproductive outcomes of 105 malignant ovarian germ cell tumor survivors: a multicenter study. Am J Obstet Gynecol 219(4):385CrossRef Tamauchi S, Kajiyama H, Yoshihara M, Ikeda Y, Yoshikawa N, Nishino K, Utsumi F, Niimi K, Suzuki S, Kikkawa F (2018) Reproductive outcomes of 105 malignant ovarian germ cell tumor survivors: a multicenter study. Am J Obstet Gynecol 219(4):385CrossRef
2.
Zurück zum Zitat Smith HO, Berwick M, Verschraegen CF, Wiggins C, Lansing L, Muller CY, Qualls CR (2006) Incidence and survival rates for female malignant germ cell tumors. Obstet Gynecol 107(5):1075–1085CrossRef Smith HO, Berwick M, Verschraegen CF, Wiggins C, Lansing L, Muller CY, Qualls CR (2006) Incidence and survival rates for female malignant germ cell tumors. Obstet Gynecol 107(5):1075–1085CrossRef
3.
Zurück zum Zitat Quirk JT, Natarajan N (2005) Ovarian cancer incidence in the United States, 1992–1999. Gynecol Oncol 97(2):519–523CrossRef Quirk JT, Natarajan N (2005) Ovarian cancer incidence in the United States, 1992–1999. Gynecol Oncol 97(2):519–523CrossRef
4.
Zurück zum Zitat Williams SD (1989) Cisplatin, vinblastine, and bleomycin in advanced and recurrent ovarian germ-cell tumors. Ann Intern Med 111(1):22CrossRef Williams SD (1989) Cisplatin, vinblastine, and bleomycin in advanced and recurrent ovarian germ-cell tumors. Ann Intern Med 111(1):22CrossRef
5.
Zurück zum Zitat Yang Z-J, Liu Z-C, Wei R-J, Li L (2015) An analysis of prognostic factors in patients with ovarian malignant germ cell tumors who are treated with fertility-preserving surgery. Gynecol Obstet Invest 81(1):1–9CrossRef Yang Z-J, Liu Z-C, Wei R-J, Li L (2015) An analysis of prognostic factors in patients with ovarian malignant germ cell tumors who are treated with fertility-preserving surgery. Gynecol Obstet Invest 81(1):1–9CrossRef
6.
Zurück zum Zitat Park J-Y, Kim D-Y, Suh D-S, Kim J-H, Kim Y-M, Kim Y-T, Nam J-H (2017) Analysis of outcomes and prognostic factors after fertility-sparing surgery in malignant ovarian germ cell tumors. Gynecol Oncol 145(3):513–518CrossRef Park J-Y, Kim D-Y, Suh D-S, Kim J-H, Kim Y-M, Kim Y-T, Nam J-H (2017) Analysis of outcomes and prognostic factors after fertility-sparing surgery in malignant ovarian germ cell tumors. Gynecol Oncol 145(3):513–518CrossRef
7.
Zurück zum Zitat Perrin LC, Low J, Nicklin JL, Ward BG, Crandon AJ (1999) Fertility and ovarian function after conservative surgery for germ cell tumours of the ovary. Austral N Zeal J Obstet Gynaecol 39(2):243–245CrossRef Perrin LC, Low J, Nicklin JL, Ward BG, Crandon AJ (1999) Fertility and ovarian function after conservative surgery for germ cell tumours of the ovary. Austral N Zeal J Obstet Gynaecol 39(2):243–245CrossRef
8.
Zurück zum Zitat Low JJH, Perrin LC, Crandon AJ, Hacker NF (2000) Conservative surgery to preserve ovarian function in patients with malignant ovarian germ cell tumors. Cancer 89(2):391–398CrossRef Low JJH, Perrin LC, Crandon AJ, Hacker NF (2000) Conservative surgery to preserve ovarian function in patients with malignant ovarian germ cell tumors. Cancer 89(2):391–398CrossRef
9.
Zurück zum Zitat Qin B, Xu W, Li Y (2019) Are omentectomy and lymphadenectomy necessary in patients with apparently early-stage malignant ovarian germ cell tumors? Int J Gynecol Cancer 29(2):398–403CrossRef Qin B, Xu W, Li Y (2019) Are omentectomy and lymphadenectomy necessary in patients with apparently early-stage malignant ovarian germ cell tumors? Int J Gynecol Cancer 29(2):398–403CrossRef
10.
Zurück zum Zitat Mahdi H, Swensen RE, Hanna R, Kumar S, Ali-Fehmi R, Semaan A, Tamimi H, Morris RT, Munkarah AR (2011) Prognostic impact of lymphadenectomy in clinically early stage malignant germ cell tumour of the ovary. Br J Cancer 105(4):493–497CrossRef Mahdi H, Swensen RE, Hanna R, Kumar S, Ali-Fehmi R, Semaan A, Tamimi H, Morris RT, Munkarah AR (2011) Prognostic impact of lymphadenectomy in clinically early stage malignant germ cell tumour of the ovary. Br J Cancer 105(4):493–497CrossRef
11.
Zurück zum Zitat Park J-Y, Kim D-Y, Suh D-S, Kim J-H, Kim Y-M, Kim Y-T, Nam J-H (2016) Significance of the complete surgical staging of stage i malignant ovarian germ cell tumors. Ann Surg Oncol 23(9):2982–2987CrossRef Park J-Y, Kim D-Y, Suh D-S, Kim J-H, Kim Y-M, Kim Y-T, Nam J-H (2016) Significance of the complete surgical staging of stage i malignant ovarian germ cell tumors. Ann Surg Oncol 23(9):2982–2987CrossRef
12.
Zurück zum Zitat Xu W, Li Y (2017) Is Omentectomy mandatory among early stage (I, II) malignant ovarian germ cell tumor patients? A retrospective study of 223 cases. Int J Gynecol Cancer 27(7):1373–1378CrossRef Xu W, Li Y (2017) Is Omentectomy mandatory among early stage (I, II) malignant ovarian germ cell tumor patients? A retrospective study of 223 cases. Int J Gynecol Cancer 27(7):1373–1378CrossRef
13.
Zurück zum Zitat Prat J (2015) FIGOs staging classification for cancer of the ovary, fallopian tube, and peritoneum: abridged republication. J Gynecol Oncol 26(2):87CrossRef Prat J (2015) FIGOs staging classification for cancer of the ovary, fallopian tube, and peritoneum: abridged republication. J Gynecol Oncol 26(2):87CrossRef
14.
Zurück zum Zitat Gershenson DM (2007) Management of ovarian germ cell tumors. J Clin Oncol 25(20):2938–2943CrossRef Gershenson DM (2007) Management of ovarian germ cell tumors. J Clin Oncol 25(20):2938–2943CrossRef
15.
Zurück zum Zitat Chan JK, Tewari KS, Waller S, Cheung MK, Shin JY, Osann K, Kapp DS (2008) The influence of conservative surgical practices for malignant ovarian germ cell tumors. J Surg Oncol 98(2):111–116CrossRef Chan JK, Tewari KS, Waller S, Cheung MK, Shin JY, Osann K, Kapp DS (2008) The influence of conservative surgical practices for malignant ovarian germ cell tumors. J Surg Oncol 98(2):111–116CrossRef
16.
Zurück zum Zitat Tangir J, Zelterman D, Ma W, Schwartz PE (2003) Reproductive function after conservative surgery and chemotherapy for malignant germ cell tumors of the ovary. Obstet Gynecol 101(2):251–257PubMed Tangir J, Zelterman D, Ma W, Schwartz PE (2003) Reproductive function after conservative surgery and chemotherapy for malignant germ cell tumors of the ovary. Obstet Gynecol 101(2):251–257PubMed
17.
Zurück zum Zitat Karalok A, Comert GK, Kilic C, Turkmen O, Kilic F, Basaran D, Boyraz G, Tekin ÖM, Turan T (2019) Cytoreductive surgery in advanced stage malignant ovarian germ cell tumors. J Gynecol Obstet Hum Reprod 48(7):461–466CrossRef Karalok A, Comert GK, Kilic C, Turkmen O, Kilic F, Basaran D, Boyraz G, Tekin ÖM, Turan T (2019) Cytoreductive surgery in advanced stage malignant ovarian germ cell tumors. J Gynecol Obstet Hum Reprod 48(7):461–466CrossRef
18.
Zurück zum Zitat Mangili G, Sigismondi C, Lorusso D, Cormio G, Candiani M, Scarfone G, Mascilini F, Gadducci A, Mosconi AM, Scollo P, Cassani C, Pignata S, Ferrandina G (2016) The role of staging and adjuvant chemotherapy in stage I Malignant ovarian germ cell tumors (MOGTs): the MITO-9 study. Ann Oncol 28:333–338CrossRef Mangili G, Sigismondi C, Lorusso D, Cormio G, Candiani M, Scarfone G, Mascilini F, Gadducci A, Mosconi AM, Scollo P, Cassani C, Pignata S, Ferrandina G (2016) The role of staging and adjuvant chemotherapy in stage I Malignant ovarian germ cell tumors (MOGTs): the MITO-9 study. Ann Oncol 28:333–338CrossRef
21.
Zurück zum Zitat Pectasides D, Pectasides E, Kassanos D (2008) Germ cell tumors of the ovary. Cancer Treat Rev 34(5):427–441CrossRef Pectasides D, Pectasides E, Kassanos D (2008) Germ cell tumors of the ovary. Cancer Treat Rev 34(5):427–441CrossRef
22.
Zurück zum Zitat Bafna UD, Umadevi K, Kumaran C, Nagarathna DS, Shashikala P, Tanseem R (2001) Germ cell tumors of the ovary: is there a role for aggressive cytoreductive surgery for nondysgerminomatous tumors? Int J Gynecol Cancer 11(4):300–304CrossRef Bafna UD, Umadevi K, Kumaran C, Nagarathna DS, Shashikala P, Tanseem R (2001) Germ cell tumors of the ovary: is there a role for aggressive cytoreductive surgery for nondysgerminomatous tumors? Int J Gynecol Cancer 11(4):300–304CrossRef
23.
Zurück zum Zitat Lai C-H, Chang T-C, Hsueh S, Wu T-I, Chao A, Chou H-H, Wang P-N (2005) Outcome and prognostic factors in ovarian germ cell malignancies. Obstet Gynecol Surv 60(6):364–365CrossRef Lai C-H, Chang T-C, Hsueh S, Wu T-I, Chao A, Chou H-H, Wang P-N (2005) Outcome and prognostic factors in ovarian germ cell malignancies. Obstet Gynecol Surv 60(6):364–365CrossRef
24.
Zurück zum Zitat Lee CW, Song MJ, Park ST, Ki EY, Lee SJ, Lee KH, Ryu KS, Park JS, Hur SY (2011) Residual tumor after the salvage surgery is the major risk factors for primary treatment failure in malignant ovarian germ cell tumors: a retrospective study of single institution. World J Surg Oncol 9(1):123CrossRef Lee CW, Song MJ, Park ST, Ki EY, Lee SJ, Lee KH, Ryu KS, Park JS, Hur SY (2011) Residual tumor after the salvage surgery is the major risk factors for primary treatment failure in malignant ovarian germ cell tumors: a retrospective study of single institution. World J Surg Oncol 9(1):123CrossRef
29.
Zurück zum Zitat Mitchell P, Al-Nasiri N, A'Hern R, Fisher C, Horwich A, Pinkerton C, Shepherd J, Gallagher C, Slevin M, Harper P, Osborne R, Mansi J, Oliver T, Gore M (1999) Treatment of nondysgerminomatous ovarian germ cell tumors. Cancer 85(10):2232–2244CrossRef Mitchell P, Al-Nasiri N, A'Hern R, Fisher C, Horwich A, Pinkerton C, Shepherd J, Gallagher C, Slevin M, Harper P, Osborne R, Mansi J, Oliver T, Gore M (1999) Treatment of nondysgerminomatous ovarian germ cell tumors. Cancer 85(10):2232–2244CrossRef
Metadaten
Titel
Fertility-sparing surgery for patients with malignant ovarian germ cell tumors: 10 years of clinical experience from a tertiary referral center
verfasst von
Mislav Mikuš
Nikolina Benco
Luka Matak
Pavao Planinić
Mario Ćorić
Helena Lovrić
Velena Radošević
Tomislav Puževski
Mirna Bajt
Goran Vujić
Publikationsdatum
06.04.2020
Verlag
Springer Berlin Heidelberg
Erschienen in
Archives of Gynecology and Obstetrics / Ausgabe 5/2020
Print ISSN: 0932-0067
Elektronische ISSN: 1432-0711
DOI
https://doi.org/10.1007/s00404-020-05522-5

Neu im Fachgebiet Gynäkologie und Geburtshilfe

Osteoporose-Indizes offenbar wenig sinnvoll bei jüngeren Frauen

In einer US-Studie war keiner von drei getesteten Osteoporose-Indizes verlässlich genug, um bei postmenopausalen Frauen unter 65 Jahren ein klinisch relevantes Frakturrisiko zu erkennen.

Einleitung bei Zwillingsgeburt mit Sectiorisiko assoziiert

Einleitung ja oder nein? Besonders bei Schwangerschaften mit Zwillingen ist diese Entscheidung relevant. Wird die Geburt eingeleitet, steigt das Risiko für eine Sectio deutlich. Das hat nun eine Studie aus der Schweiz ergeben.

Junge Brustkrebspatientinnen zum Durchhalten motivieren

Patientinnen, die in jungen Jahren an Hormonrezeptor-positivem Brustkrebs erkranken, neigen dazu, die adjuvante endokrine Therapie auszusetzen oder abzubrechen. Die schlechte Therapiepersistenz scheint die Rückkehr des Tumors zu begünstigen.

Krebsscreeningprogramme erreichen Menschen mit kognitiver Beeinträchtigung schlechter

Daten aus den Niederlanden zeigen, dass Krebsfrüherkennungsmaßnahmen für Menschen mit Störungen der Intelligenzentwicklung häufig nicht zugänglich sind. Wie kann diese Lücke geschlossen werden?

Update Gynäkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert – ganz bequem per eMail.